GRFS Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of 3.49% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 2.53% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Grifols SA has a consensus price target of $10.20, signalling upside risk potential of 53.38%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 970.51%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Grifols SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Grifols SA.

Grifols SA has a beta of 0.413, which suggesting that the stock is 58.693% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.

Grifols SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays 0.61% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Grifols SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Grifols SA quarterly revenues are $2.1B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Grifols SA's net income of $73.5M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Grifols SA's price-to-earnings ratio is 20.16x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.58x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of 3.49% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 2.53% beat DBV Technologies SA's return on equity of --.

Grifols SA has a consensus price target of $10.20, signalling upside risk potential of 53.38%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 246.92%. Given that DBV Technologies SA has higher upside potential than Grifols SA, analysts believe DBV Technologies SA is more attractive than Grifols SA.

Grifols SA has a beta of 0.413, which suggesting that the stock is 58.693% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 108.034%.

Grifols SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays 0.61% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Grifols SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Grifols SA quarterly revenues are $2.1B, which are larger than DBV Technologies SA quarterly revenues of --. Grifols SA's net income of $73.5M is higher than DBV Technologies SA's net income of -$23M. Notably, Grifols SA's price-to-earnings ratio is 20.16x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.58x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of 3.49% compared to Grifols SA's net margin of 32.95%. Grifols SA's return on equity of 2.53% beat Novo Nordisk AS's return on equity of 86.85%.

Grifols SA has a consensus price target of $10.20, signalling upside risk potential of 53.38%. On the other hand Novo Nordisk AS has an analysts' consensus of $106.03 which suggests that it could grow by 69.52%. Given that Novo Nordisk AS has higher upside potential than Grifols SA, analysts believe Novo Nordisk AS is more attractive than Grifols SA.

Grifols SA has a beta of 0.413, which suggesting that the stock is 58.693% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.645%.

Grifols SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.58% to investors and pays a quarterly dividend of $1.10 per share. Grifols SA pays 0.61% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Grifols SA quarterly revenues are $2.1B, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Grifols SA's net income of $73.5M is lower than Novo Nordisk AS's net income of $4B. Notably, Grifols SA's price-to-earnings ratio is 20.16x while Novo Nordisk AS's PE ratio is 19.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.58x versus 6.63x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.